PADCEV succeeds in confirmatory phase 3 trial in urothelial cancer

This article was originally published here

The global trial called EV-301 compared PADCEV to chemotherapy in nearly 600 patients who had prior treatment with platinum-based chemotherapy and a PD-1/L1 inhibitor. Co-developed by the two

The post PADCEV succeeds in confirmatory phase 3 trial in urothelial cancer appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply